Cocrystal Pharma, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Nine months ended September 30,
2025 · 2024
Operating activities:
Net loss		$(6,405)	$(14,238)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		59	98
Right of use assets		226	247
Stock-based compensation		214	558
Operating lease liabilities		(223)	(142)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(96)	1,281
Tax credit receivable		702	238
Accounts payable and accrued expenses		(933)	(1,367)
Net cash used in operating activities		(6,456)	(13,325)
Investing activities:
Purchases of property and equipment		(12)	(8)
Net cash used in investing activities		(12)	(8)
Financing activities:
Proceeds from ATM sale of common stock, net of transaction costs		154	-
Proceeds from registered direct sale of common stock, net of transaction cost		4,183	-
Net cash provided by financing activities		4,337	-
Net decrease in cash and restricted cash		(2,131)	(13,333)
Cash and restricted cash at beginning of period		9,935	26,428
Cash and restricted cash at end of period		$7,804	$13,095
Supplemental disclosure:
Non-cash investing and financing activities
Initial recognition of right-of-use assets and lease liabilities	$	-	$163

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.